Publications – Prof. Dr. Pierre Koch (*as Corresponding Author)

Research articles, reviews:

2025

84. Wydra, V. R., Plank, N., Zwirner, S., Selig, R., Rasch, A., Masberg, B., Lämmerhofer, M., Zender, L, Koch, P., Albrecht, W., Laufer, S. A. "Ligand First" Approach toward Selective, Covalent JNK2/3 Inhibitors. ***J. Med. Chem.*** 2025, asap. https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00884
83. Schettler, F., Gattor, A. **Koch, P.**, Keller, M. Characterization of [^{3}H]Propionylated Human Peptide YY – a New Probe for Neuropeptide Y Y_2 Receptor Binding Studies. ***ACS Pharmacol. Transl. Sci.,*** ASAP, 2025, *8*, 785-799.

2024

82. Martorelli, M., Dengler, M., Laux, J., Fischer, T., Vaiceliunaite, A., Hahn, U., Cruces, S. Pokoj, C., de Oliveira de Cunha, L., Wohlbold, L., **Koch, P.**, Laufer, S., Burnet, M., Maier, F. A Defined Diet Combined with Sonicated Inoculum Provides a High Incidence, Moderate Severity Form of Experimental Autoimmune Encephalomyelitis (EAE). ***ACS Pharmacol. Transl. Sci.,*** 2024, *7*, 3827-3845.
81 **Koch, P.**, Schollmeyer, D. 1-[(2-Chlorophenyl)diphenylmethyl]-1*H*-pyrazole. ***IUCr data*** 2024, *8,* x241152.
80. Scheuerer, S., Motlova, L., Schäker-Hübner, L., Sellmer, A., Feller, F., Ertl, F. J., **Koch, P.**, Hansen, F. K., Barinka, C., Mahboobi, S. Biological and structural investigation of tetrahydro-β-carboline-based selective HDAC6 inhibitors with improved stability. ***Eur. J. Med. Chem.*** 2024, *276*, 116676.
79. Ganser, K., Stansky, N., Abed, T., Quintanilla-Martinez, L., Gonzalez-Menendez, I., Naumann, U., **Koch, P.**, Krueger, M., Ruth, P., Huber, S. M., Eckert, F. K_{Ca} channel targeting impairs DNA repair and invasiveness of patient-derived glioblastoma stem cells in culture and orthotopic mouse xenografts which only in part is predictable by K_{Ca} expression levels. ***Int. J. Cancer.*** 2024, 155, 1886-1901.

2023

78. Stansky, N., Ganser, K., Quintanilla-Martinez, L., Gonzalez-Menendez, I., Naumann, U., Eckert, F. **Koch, P.**, Huber, S. M., Ruth, P. Efficacy of combined tumor irradiation and K_{Ca}3.1-targeting with TRAM-34 in a syngeneic glioma mouse model. ***Sci. Rep.*** 2023, *13*, 202604.
77. Hoffelner, B. S., Andreev, S., Plank, N., **Koch, P.*** Photocaging of Pyridinylimidazole-Based Covalent JNK3 Inhibitors Affords Spatiotemporal Control of the Binding Affinity in Live Cells. ***Pharmaceuticals*** 2023, *16*, 246.

2022

76. Müller, C., Gleixner, J., Tahk, M.-J., Kopanchuk, S., Laasfeld, T., Weinhart, M., Schollmeyer, D. Betschart, M. U., Lüdeke, S., **Koch, P.**, Rinken, A., Keller, M. Structure-based design of high-affinity fluorescent probes for the neuropeptide Y Y1 receptor. ***J. Med. Chem.,*** 2022, *65*, 4832-4853.
75. Andreev, S., Pantsar, T., Tesch, R., Kahlke, N., El-Gokha, A., Ansideri, F., Grätz, L., Romasco, J., Sita, G., Geibel, C., Lämmerhofer, M., Tarozzi, A., Knapp, S., Laufer, S. A., **Koch, P.*** Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-based Glycogen Synthase Kinase-3β inhibitors. ***J. Med. Chem.*** 2022, *65*, 1283-1301.
74. Tormählen, N. W., Martorelli, M., Kuhn, A., Maier, F., Guezguez, J., Burnet, M., Albrecht, W., Laufer, S. A., **Koch, P.*** Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors. ***J. Med. Chem.*** 2022, *65*, 1225-1242.
73. Andreev, S., Plank, N., Schollmeyer, D., **Koch, P.*** (*S*)-3-(3-((7-Ethynyl-9H-pyrimido[4,5-*b*]indol-4-yl)amino)piperidin-1-yl)propanenitrile. ***Molbank*** 2022, *2022*, M1437.

72. Boskovic, M., Andreev, S., Schollmeyer, D., **Koch, P.*** 12*H*-Dibenzo[*d*,*g*][1,2,3]triselenocin-12-ol. ***Molbank*** 2022, *2022*, M1418.

2021

71. Schade, N., **Koch, P.**, Ansideri, F., Krystof, V., Hilgeroth, A. Evaluation of Novel Substituted Furopyridines as Inhibitors of Protein Kinases Related to Tau Pathology in Alzheimer´s Disease. ***Med. Chem. (Sharjah, United Arab Emirates)*** 2021, 17, 844-855.
70. Reynders, M. Chaikuad, A., Berger, B.-T., Bauer, K., **Koch, P.**, Laufer, S., Knapp, S., Trauner, D. Controlling the Covalent Reactivity of a Kinase Inhibitor with Light. ***Angew. Chem. Int. Ed.*** 2021*, 60*, 20178-20183.
69. Eitel, M., Zinad, D., Schollmeyer, D., Gross, H., **Koch, P.*** Selective Mono-de-O-acetylation of the Per-O-acetylated Brasilicardin Carbohydrate Side Chain. ***Carbohydrate Res.*** 2021, *504*, 108312.
68. Andreev, S., Schollmeyer, D., **Koch, P.*** 1-(3-((7-Fluoro-9*H*-pyrimido[4,5-*b*]indol-4-yl)(methyl) amino)piperidin-1-yl)propan-1-one. ***IUCr data*** *6*, x210159.
67. Botas, A., Eitel, M., Schwarz, P. N., Buchmann, A., Costales, P., Núñez, L. E., Cortés, J., Morís, F., Krawiec, M., Wolański, M., Gust, B., Rodriguez, M., Fischer, W.-N., Jandeleit, B., Zakrzewska-Cerwińska, J., Wohlleben, W., Stegmann, E., **Koch, P.,*** Méndez, C., Gross, H. Genetic engineering in combination with semisynthesis leads to a new route for gram-scale production of the immunosuppressive natural product brasilicardin A. ***Angew. Chem. Int. Ed.*** 2021, *60*, 13536-13541.
66. Wolański, M., Krawiec, M., Schwarz, P.N., Stegmann, E., Wohlleben, W., Buchmann, A., Gross, H., Eitel, M., **Koch, P.**, Botas, A., Méndez, C., Núñez, L.E., Morís, F., Cortés, J., Zakrzewska-Czerwińska, J. LysRNt: A novel regulator involved in the biosynthesis of the immunosuppressant brasilicardin. ***Eng. Life Sci.*** 2021, *21*, 4-18.

2020

65. Majer, T., Schollmeyer, D., **Koch, P.**, Gross, H. (*2S,3'S,3a'R,5'R,7a'R*)-5'-((*E*)-5-(Furan-3-yl)-2-methylpent-1-en-1-yl)-3-hydroxy-3',4,7'-trimethyl-1',2',3',3a',5',7a'-hexahydro-5*H*-spiro[furan-2,4'-inden]-5-one. ***IUCr data*** 2020, *5,* x201578.
64. Andreev, S., Pantsar, T., El-Gokha, A., Ansideri, F., Kudolo, M., Anton, D. B., Sita, G., Romasco, J., Geibel, C., Lämmerhofer, M., Goettert, M. I., Tarozzi, A., Laufer, S. A., **Koch, P.*** Discovery and Evaluation of Enantiopure 9*H*-pyrimido[4,5-b]indoles as Nanomolar GSK-3β Inhibitors with Improved Metabolic Stability. ***Int. J. Mol. Sci.*** 2020, *21*, 7823.
63. **Koch, P.*** Inhibitors of cJun N-terminal kinase 3. In: Laufer, S. (eds) Proteinkinase Inhibitors. ***Topics in Med. Chem.*** 2020, *vol. 36***.** Springer, Cham. *https://doi.org/10.1007/7355_2020_98.*

2019

62. Heider, F., Pantsar, T., Kudolo, M., Ansideri, F., De Simone, A., Pruccoli, L., Schneider, T., Goettert, M. I., Tarozzi, A., Andrisano, V., Laufer, S. A., **Koch, P.*** Pyridinylimidazoles as GSK3β inhibitors: the impact of tautomerism on compound activity via water networks. ***ACS Med. Chem. Lett.*** 2019, *10*, 1407−1414.
61. Andreev, S., Pantsar, T., Ansideri, F., Kudolo, M., Forster, M., Schollmeyer, D., Laufer, S. A., **Koch, P.*** Design, Synthesis and Biological Evaluation of 7-Chloro-9*H*-pyrimido[4,5-*b*]indole-based Glycogen synthase kinase-3β inhibitors. ***Molecules*** 2019, *24*, 2331.
60. Heider, F., Ansideri, F., Tesch, R., Pantsar, T., Haun, U., Döring, E., Kudolo, M., Poso, A., Albrecht, W., Laufer, S. A., **Koch, P.*** Pyridinylimidazoles as dual Glycogen Synthase Kinase 3β/p38α Mitogen-activated Protein Kinase Inhibitors. ***Eur. J. Med. Chem.*** 2019, *175*, 309-329.
59. Elgokha, A., Ansideri, F., Andreev, S., Schollmeyer, D., Laufer, S. A., **Koch, P.*** N^1-{4-[2-(Methylthio)-1*H*-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine. ***Molbank*** 2019, *2019*, M1048.

2018

58. Ernst, C., Heidrich, J., Sessler, C., Sindlinger, J., Schwarzer, D., **Koch, P.**, Boeckler, F. M. Switching Between Bicyclic and Linear Peptides-The Sulfhydryl-Specific Linker TPSMB Enables Reversible Cyclization of Peptides. ***Frontiers Chem.*** 2018, *6*, 484.
57. Ernst, C., Sindlinger, J., Schwarzer, D., **Koch, P.**, Boeckler, F. M. The Symmetric Tetravalent Sulfhydryl-Specific Linker NATBA Facilitates a Combinatorial "Tool Kit" Strategy for Phage Display-Based Selection of Functionalized Bicyclic Peptides. ***ACS Omega*** 2018, *3*, 13261-12368.
56. Eitel, M., Schollmeyer, D., Gross, H, **Koch, P.*** (2*S*, 3*S*)-2-Azaniumyl-4-[(1*S*, 4a*S*, 4b*S*, 6*S*, 7*S*, 8a*S*, 10a*S*)-6,7-dihydroxy-2,4b,8,8,10a-pentamethyl-1,4,4a,4b,5,6,7,8,8a,9,10,10a-dodecahydrophenanthren-1-yl]-3-methoxybutanoate–methanol–water (1/1/1). ***IUCrData*** 2018, *3*, x181194.
55. Ansideri, F., Macedo, J. T., Eitel, M., El-Gokha, A., Zinad, D. S., Scarpellini, C., Kudolo, M., Schollmeyer, D., Boeckler, F. M., Blaum, B. S., Laufer, S. A., **Koch, P.*** Structural Optimization of a Pyridinylimidazole Scaffold: Shifting the Selectivity from p38α Mitogen-Activated Protein Kinase to c-Jun N-terminal Kinase 3. ***ACS Omega*** 2018, *3*, 7809-7831.
54. **Koch, P.**, Brunschweiger, A., Namisvajan, V., Ullrich, S., Maurca, A., Lazzaretto, B., Küppers, P., Hinz, S., Hockemeyer, J., Wiese, M., Heer, J., Alcaro, S., Kiec-Kononowicz, K., Müller, C. E. Probing substituents in the 1- and 3-position: Tetrahydropyrazino-annelated water-soluble xanthine derivatives as multi-target drugs with potent adenosine receptor antagonistic activity. ***Frontiers Chem.*** 2018, 6, 206.
53. Chaikuad, A., **Koch, P.**, Laufer, S. A., Knapp, S. Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. ***Angew. Chem.*** 2018, *130*, 4456-4470. (Review)

    Chaikuad, A., **Koch, P.**, Laufer, S. A., Knapp, S. The Cysteinome of Protein Kinases as a Target in Drug Development. ***Angew. Chem. Int. Ed.*** 2018, *57*, 4372-4385. (Review)
52. Ansideri, F., Andreev, S., Kuhn, A., Albrecht, W., Laufer, S. A., **Koch, P.*** A Diverse and Versatile Regiospecific Synthesis of Tetrasubstituted Alkylsulfanylimidazoles p38α Mitogen-Activated Protein Kinase Inhibitors. ***Molecules*** 2018, *23*, 221.

2017

51. **Koch, P.**,* Ansideri, F. 2-Alkylsulfanyl-4(5)-aryl-5(4)-heteroarylimidazoles: an Overview on Synthetic Strategies and Biological Activity. ***Arch. Pharm.***, 2017, *350*, e1700258. (Review)
50. Heider, F., Haun, U., Döring, E., Kudolo, M., Sessler, C., Albrecht, W., Laufer, S., **Koch, P.*** From 2-alkylsulfanylimidazoles to 2-alkylimidazoles: An approach towards metabolically more stable p38α MAP kinase inhibitors. ***Molecules*** 2017, *22*, 1729.
49. Eitel, M., Schollmeyer, D., **Koch, P.*** (*E*)-(1-Pyridin-4-yl)-propran-1-one *O*-tosyl oxime. ***IUCrData*** 2017, *2*, x171602.
48. Steudel, F. A, Mohr, C. J., Steegen, B., Nguyen, H. Y., Barnert, A., Steinle, M., Berr-Hammer, S., **Koch, P.**, Lo, W.-Y., Schroth, W., Hoppe, R., Brauch, H., Ruth, P., Huber, S. M., Lukowski, R. SK4 channels modulate Ca^{2+}-signalling and cell cycle progression in murine breast cancer. ***Mol. Oncol.*** 2017, *11*, 1172-1188.
47. Ansideri, F., Dammann, M., Boeckler, F. M., **Koch, P.*** Fluorescence polarization-based competition binding assay for c-Jun N-terminal kinases 1 and 2. ***Anal. Biochem.*** 2017, *532*, 26-28.
46. Muth, F., El-Gokha, A., Ansideri, F., Eitel, M., Döring, E. Sievers-Engler, A., Lange, A., Boeckler, F. M., Lämmerhofer, M., **Koch, P.**,* Laufer, S. A. Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c−Jun N−Terminal Kinase 3. ***J. Med. Chem.*** 2017, *60*, 594−607.

2016

45. Buchmann, A., Eitel M., **Koch, P.**, Schwarz, P. N., Stegmann, E., Wohlleben, W., Wolański, M., Krawiec, M., Zakrzewska-Czerwińska, J., Méndez, C., Botas, A., Núñez, L. E., Morís, F., Cortés, J., Gross, H. High-Quality Draft Genome Sequence of the Actinobacterium *Nocardia terpenica IFM*

0406, Producer of the Immunosuppressant Brasilicardins, Using Illumina and PacBio Technologies. ***Genome Announc.*** 2016, *4*, e01391-16.

44. Brunschweiger, A., **Koch, P.**, Schlenk, M., Rafehi, M., Radjainia, H., Küppers, P., Hinz, H., Pineda, F., Wiese, M., Hockemeyer, J., Heer, J., Denonne, F., Müller, C. E. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-*f*]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors. ***Bioorg. Med. Chem.*** 2016, *24*, 5462-5480.
43. Ansideri, F., Lange, A., El-Gokha A., Boeckler, F. M., **Koch, P**.* Fluorescence polarization-based assay for detecting compounds binding to inactive JNK3 and p38α MAP Kinase. ***Anal. Biochem.*** 2016, *503*, 28-40.
42. Ansideri, F., Schollmeyer, D., **Koch, P.*** 1-(3',6'-Dihydroxy-3-oxo-3*H*-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-3-[4-({4-[1-(4-fluorophenyl)-1*H*-imidazol-5-yl]pyridin-2-yl}amino)phenyl]thiourea methanol monosolvate. ***IUCrData*** 2016, *1*, x1608040.
41. El-Gokha A., Schollmeyer, D., **Koch, P.*** 4-Methyl-*N*-(4-methylpyridin-2-yl)-*N*-(3,4,5,6-tetrahydro-2*H*-pyran-4-yl)pyridin-2-amine. ***IUCrData*** 2016, *1*, x160804.
40. Eitel, M., Schollmeyer, D., **Koch, P.*** (*E*)-(1-Pyridin-4-yl)-propran-1-one oxime. ***IUCrData*** 2016, *1*, x160803.

2015

39. Lange, A., Günther, M., Buettner, F. M., Zimmermann, M. O., Heidrich, J., Hennig, S., Zahn, S., Schall, C., Sievers-Engler, A., Ansideri, F., **Koch, P.**, Laemmerhofer, M., Stehle, T., Laufer, S. A., Boeckler, F. M. Targeting the Gatekeeper MET146 of c-Jun N-terminal kinase 3 (JNK3) Induces a Bivalent Halogen / Chalcogen Bond. ***J. Am. Chem. Soc.*** 2015, *137*, 14640-14652.
38. Jung, M. E., Chamberlain, B. T., **Koch, P.**, Niazi, K. R. Synthesis and Biological Actvity of a Brasilicardin A Analogue Featuring a Simplified Core. ***Org. Lett*.** 2015, *17*, 3608-3611.
37. Elgokha, A., Laufer, S. A., **Koch, P**.* An optimized and versatile synthesis to pyridinylimidazole-type p38α mitogen activated protein kinase inhibitors. ***Org. Biomol. Chem.*** 2015, *13*, 10699-10704.
36. Gehringer, M., Muth, F., **Koch, P.**, Laufer, S. A. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). ***Expert Opin. Ther. Pat.*** 2015, *25*, 849-872. (Review)
35. Muth, F., Günther, M., Bauer, S. M., Döring, E., Fischer, S., Maier, J., Drückes, P., Köppler, J., Trappe, J., Rothbauer, U., **Koch, P.**, Laufer, S. A. Tetra-Substituted Pyridinylimidazoles As Dual Inhibitors of p38α Mitogen-Activated Protein Kinase and c-Jun N-Terminal Kinase 3 for Potential Treatment of Neurodegenerative Diseases. ***J. Med. Chem.*** 2015, *58*, 443-456.
34. **Koch, P.,*** Gehringer, M., Laufer, S. A. Inhibitors of c-Jun N-terminal kinase (an update). ***J. Med. Chem.*** 2015, *58*, 72-95. (Review).

2014

33. Zimmermann, M. O., Lange, A., Wicken, R., Cieslik, M. B., Exner, T. E., Joerger, J. C., **Koch, P.**, Boeckler, F. M. Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. ***Future Med. Chem.*** 2014, *6*, 617-639. (Review)
32. Brunschweiger, A., **Koch, P.**, Schlenk, M., Pineda, F., Küppers, P., Hinz, S., Köse, M., Ullrich, S., Hockemeyer, J., Wiese, M., Heer, J., Müller, C. E. 8-Benzyltetrahydropyrazino[2,1-*f*]purinediones: Water-Soluble Tricyclic Xanthine Derivatives as Multitarget Drugs for Neurodegenerative Diseases. ***ChemMedChem*** 2014, *9*, 1704-1724.

    This publication was awarded with the Neuroallianz Publication Award 2014 – Silver Award.

2013

31. **Koch, P.**, Akkari, R., Brunschweiger A., Borrmann, T., Schlenk, M., Küppers, P., Köse, M., Radjainia, H., Hockemeyer, J., Drabczynska, A., Kiec-Kononowicz, K., Müller C. E. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. ***Bioorg. Med. Chem.*** 2013, *21*, 7435-7452.

2012

30. Abu Thaher, B., Arnsmann, M., Totzke, F., Ehlert, J. E., Kubbutat, M. H. G., Schachtele, C., Zimmermann, M. O., **Koch, P.**, Boeckler, F. M., Laufer, S. Tri- and Tetrasubstituted Pyrazole Derivates: Regioisomerism Switches Activity from p38MAP Kinase to Important Cancer Kinases. ***J. Med. Chem.*** 2012, *55*, 961-965.
29. Abu Thaher, B., **Koch, P.**, Schollmeyer, D., Laufer, S. 4-[5-Amino-4-(4-fluorophenyl)-3-(pyridin-4-yl)-1*H*-pyrazol-1-yl]benzonitrile. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2012, *E68*, o935.
28. Abu Thaher, B., **Koch, P.**, Schollmeyer, D., Laufer, S. Ethyl 5-amino-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1*H*-pyrazole-4-carboxylate dimethyl sulfoxide hemisolvate. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2012, *E68*, o917-918.
27. Abu Thaher, B., **Koch, P.**, Schollmeyer, D., Laufer, S. 4-(4-Fluorophenyl)-1-(4-nitrophenyl)-3-(pyridin-4-yl)-1*H*-pyrazol-5-amine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2012, *E68*, o366.
26. Abu Thaher, B., **Koch, P.**, Schollmeyer, D., Laufer, S. 4-(4-Fluorophenyl)-1-phenyl-3-(pyridin-4-yl)-1*H*-pyrazol-5-amine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2012, *E68*, o365.
25. Abu Thaher, B., **Koch, P.**, Schollmeyer, D., Laufer, S. 4-(4-Fluorophenyl)-3-(pyridin-4-yl)-1-(2,4,6-trichlorophenyl)-1*H*-pyrazol-5-amine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2012, *E68*, o2603.

2011

24. Jung, M. E., **Koch, P.** Mild, selective deprotection of PMB ethers with triflic acid/1,3-dimethoxybenzene. ***Tetrahedron Lett.*** 2011, *52*, 6051-6054.
23. Jung, M. E., **Koch, P.** An Efficient Synthesis of the Protected Carbohydrate Moiety of Brasilicardin A. ***Org. Lett.*** 2011, *13*, 3710-3713.

2010

22. Goettert, M., Schattel, V., **Koch, P.**, Merfort, I., Laufer, S. Biological Evaluation and Structural Determinants of p38α Mitogen-Activated-Protein Kinase and c-Jun-N-terminal Kinase 3 Inhibition by Flavonoids. ***ChemBioChem*** 2010, *11*, 2579-2588.
21. Laufer, S., Hauser, D., Stegmiller, T., Bracht, C., Ruff, K., Schattel, V., Albrecht, W., **Koch, P.** Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors. ***Bioorg. Med. Chem. Lett.*** 2010, *20*, 6671-6675.
20. **Koch, P.**, Schollmeyer, D., Laufer, S. 5-(4-Fluorophenyl)-4-(4-pyridyl) oxazol-2-amine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2010, *E66*, o917.
19. **Koch, P.**, Laufer, S. Unexpected Reaction of 2-Alkylsulfanylimidazoles to Imidazol-2-ones: Pyridinylimidazol-2-ones as Novel Potent p38α Mitogen-Activated Protein Kinase Inhibitors**.** ***J. Med. Chem.*** 2010, *53*, 4798-4802.
18. **Koch, P.**, Jahns, H., Schattel, V., Goettert, M. Laufer, S. Pyridinylquinoxalines and Pyridinylpyridopyrazines as Lead Compounds for Novel p38α Mitogen-Activated Protein Kinase Inhibitors. ***J. Med. Chem.*** 2010, *53*, 1128-1137.

2009

17. Abu Thaher, B., **Koch, P.**, Schattel, V., Laufer, S. Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38α Mitogen-Activated Protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors. ***J. Med. Chem.*** 2009, *52*, 2613-2617.
16. **Koch, P.**, Schollmeyer, D., Laufer, S. *N*-{4-[3-(4-Fluorophenyl)pyrido[2,3-*b*]pyrazin-2-yl]-2-pyridyl}isopropylamine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o2557.
15. **Koch, P.**, Schollmeyer, D., Laufer, S. 3-(4-Fluorophenyl)-2-(4-pyridyl) pyrido[2,3-*b*]pyrazine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o2546.
14. **Koch, P.**, Schollmeyer, D., Laufer, S. 2-(4-Fluorophenyl)-3-(4-pyridyl) pyrido[2,3-*b*]pyrazine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o2512.

13. Jahns, H., **Koch, P.**, Schollmeyer, D., Laufer, S. 3-(4-Fluorophenyl)-6-methoxy-2-(pyridin-4-yl)quinoxaline. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o1626.
12. Jahns, H., **Koch, P.**, Schollmeyer, D., Laufer, S. 1-(2-(Benzylamino)pyridin-4-yl)-2-(4-fluorophenyl)ethane-1,2-dione. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o1451.
11. **Koch, P.**, Schollmeyer, D., Laufer, S. 4-[3-(4-Fluorophenyl)quinoxalin-2-yl]-*N*-isopropylpyridin-2-amine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o1344.
10. **Koch, P.**, Schollmeyer, D., Laufer, S. 4-[5-(4-Fluorophenyl)-1*H*-imidazol-4-yl]pyridine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o573.
9. Abu Thaher, B., **Koch, P.**, Schollmeyer, D., Laufer, S. 4-[2-(4-Fluorophenyl)furan-3-yl]pyridine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o458.
8. Abu Thaher, B., **Koch, P.**, Schollmeyer, D., Laufer, S. 4-[2-(4-Fluorophenyl)-1*H*-pyrrol-3-yl]pyridine. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2009, *E65*, o457.

2008

7. **Koch, P.**, Bäuerlein, C., Jank, H., Laufer, S. Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles. ***J. Med. Chem.*** 2008, *51*, 5630-5640.
6. Laufer, S., **Koch, P.** Towards the improvement of the synthesis of novel 4(5)-aryl-5(4)-heteroaryl-2-thio-substituted imidazoles and their p38 MAP kinase inhibitory activity. ***Org. Biomol. Chem.*** 2008, *6*, 437-439.
5. **Koch, P.**, Schollmeyer, D., Laufer, S. *tert*-Butyl *N*-benzyl-*N*-(4-methyl-2-pyridyl)carbamate. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2008, *E64*, o2222.
4. **Koch, P.**, Schollmeyer, D., Laufer, S. *tert*-Butyl *N*-benzyl-*N*-[4-(4-fluorobenzoylmethyl)-2-pyridyl]carbamate. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2008, *E64*, o2221.
3. **Koch, P.**, Schollmeyer, D., Laufer, S. *tert*-Butyl *N*-(4-methyl-2-pyridyl)carbamate. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2008, *E64*, o2216.
2. **Koch, P.**, Bäuerlein, C., Schollmeyer, D., Laufer, S. Methyl 4-[5-(4-fluorophenyl)-4-(pyridin-4-yl)-1*H*-imidazol-2-ylsulfanyl]butanoate. ***Acta Crystallogr., Sect. E: Struct. Rep. Online*** 2008, *E64*, o1883-o1884.
1. Abu Thaher, B., **Koch, P.**, Del Amo, V., Knochel, P., Laufer, S. A convenient synthesis of 1-(4-fluorophenyl)-2-(4-pyridyl)cyclopentene from cyclopentanone. ***Synthesis*** 2008, 225-228.

Patents:

2. **Koch, P.**, Laufer, S., Wolfgang, A., Walter, N. CENTRALLY ACTIVE P38ALPHA MAP KINASE INHIBITING COMPOUNDS. WO **2021**/038292 A1.
1. Burnet, M., Laufer, S. **Koch, P.** 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS. U.S. Pat. Appl. Publ. **2009**, US US 8,143,294 B2.